Go to
JCI Insight
Citations to this article
Michael C. Haffner, … , William G. Nelson, Srinivasan Yegnasubramanian
Published October 25, 2013
Citation Information: J Clin Invest. 2013;123(11):4918-4922. https://doi.org/10.1172/JCI70354.
Citation Information: J Clin Invest. 2013;123(11):4918-4922. https://doi.org/10.1172/JCI70354.
Abstract
Recent controversies surrounding prostate cancer overtreatment emphasize the critical need to delineate the molecular features associated with progression to lethal metastatic disease. Here, we have used whole-genome sequencing and molecular pathological analyses to characterize the lethal cell clone in a patient who died of prostate cancer. We tracked the evolution of the lethal cell clone from the primary cancer to metastases through samples collected during disease progression and at the time of death. Surprisingly, these analyses revealed that the lethal clone arose from a small, relatively low-grade cancer focus in the primary tumor, and not from the bulk, higher-grade primary cancer or from a lymph node metastasis resected at prostatectomy. Despite being limited to one case, these findings highlight the potential importance of developing and implementing molecular prognostic and predictive markers, such as alterations of tumor suppressor proteins PTEN or p53, to augment current pathological evaluation and delineate clonal heterogeneity. Furthermore, this case illustrates the potential need in precision medicine to longitudinally sample metastatic lesions to capture the evolving constellation of alterations during progression. Similar comprehensive studies of additional prostate cancer cases are warranted to understand the extent to which these issues may challenge prostate cancer clinical management.
Authors
Michael C. Haffner, Timothy Mosbruger, David M. Esopi, Helen Fedor, Christopher M. Heaphy, David A. Walker, Nkosi Adejola, Meltem Gürel, Jessica Hicks, Alan K. Meeker, Marc K. Halushka, Jonathan W. Simons, William B. Isaacs, Angelo M. De Marzo, William G. Nelson, Srinivasan Yegnasubramanian
Total citations by year
Citation information
Citations to this article (265)
| Title and authors | Publication | Year |
|---|---|---|
|
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages
Pedrani M, Barizzi J, Salfi G, Nepote A, Testi I, Merler S, Castelo-Branco L, Mestre RP, Turco F, Tortola L, Theurillat JP, Gillessen S, Vogl U |
International Journal of Molecular Sciences | 2025 |
|
Evolutionary paths towards metastasis.
Naxerova K |
Nature reviews. Cancer | 2025 |
|
Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice
Rosinha A, Rabaça C, Calais F, Pinto JM, Barreira JV, Fernandes R, Ramos R, Fialho AC, Palma dos Reis J |
Frontiers in Oncology | 2024 |
|
Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features
Rao S, Verrill C, Cerundolo L, Alham NK, Kaya Z, O\u2019Hanlon M, Hayes A, Lambert A, James M, Tullis ID, Niederer J, Lovell S, Omer A, Lopez F, Leslie T, Buffa F, Bryant RJ, Lamb AD, Vojnovic B, Wedge DC, Mills IG, Woodcock DJ, Tomlinson I, Hamdy FC |
Genome Medicine | 2024 |
|
From biology to the clinic - exploring liver metastasis in prostate cancer.
Ni X, Wei Y, Li X, Pan J, Fang B, Zhang T, Lu Y, Ye D, Zhu Y |
Nature Reviews Urology | 2024 |
|
Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis.
Singhal U, Nallandhighal S, Tosoian JJ, Hu K, Pham TM, Stangl-Kremser J, Liu CJ, Karim R, Plouffe KR, Morgan TM, Cieslik M, Lucianò R, Shariat SF, Finocchio N, Dambrosio L, Doglioni C, Chinnaiyan AM, Tomlins SA, Briganti A, Palapattu GS, Udager AM, Salami SS |
Nature Communications | 2024 |
|
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
Dena Rhinehart, Jiaying Lai, David Sanin, Varsha Vakkala, Adrianna Mendes, Christopher Bailey, Emmanuel Antonarakis, Xiaojun Wu, Tamara Lotan, Rachel Karchin, Laura Sena |
NPJ precision oncology | 2024 |
|
Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review)
Jin C, Liao S, Lu G, Geng BD, Ye Z, Xu J, Ge G, Yang D |
Molecular medicine reports | 2024 |
|
Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study.
Zhou Q, Li R, Wu S, Zhang Y, Wang W, Zhu K, Wang M, Huang Z, Duan F |
La Radiologia medica | 2024 |
|
The diagnostic performance of indocyanine green for the sentinel node biopsy in prostate cancer: A systematic review and meta-analysis
Ma S, Sun J, Xu J, An Y, Xu M, Liu C, Zhang S, Miao L, Zhong X, Zeng N, He H, Wang S, Xia Q |
Asian Journal of Urology | 2024 |
|
Lymphatic Dissemination in Prostate Cancer: Features of the Transcriptomic Profile and Prognostic Models
Pudova EA, Kobelyatskaya AA, Katunina IV, Snezhkina AV, Fedorova MS, Pavlov VS, Bakhtogarimov IR, Lantsova MS, Kokin SP, Nyushko KM, Alekseev BY, Kalinin DV, Melnikova NV, Dmitriev AA, Krasnov GS, Kudryavtseva AV |
International journal of molecular sciences | 2023 |
|
Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications
Nguyen TT, Hamdan D, Angeli E, Feugeas JP, Le QV, Pamoukdjian F, Bousquet G |
Cancers | 2023 |
|
The evolution of non-small cell lung cancer metastases in TRACERx.
Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J, Johnson D, Rowan A, Razaq M, Akther M, Naceur-Lombardelli C, Prymas P, Toncheva A, Hessey S, Dietzen M, Colliver E, Frankell AM, Bunkum A, Lim EL, Karasaki T, Abbosh C, Hiley CT, Hill MS, Cook DE, Wilson GA, Salgado R, Nye E, Stone RK, Fennell DA, Price G, Kerr KM, Naidu B, Middleton G, Summers Y, Lindsay CR, Blackhall FH, Cave J, Blyth KG, Nair A, Ahmed A, Taylor MN, Procter AJ, Falzon M, Lawrence D, Navani N, Thakrar RM, Janes SM, Papadatos-Pastos D, Forster MD, Lee SM, Ahmad T, Quezada SA, Peggs KS, Van Loo P, Dive C, Hackshaw A, Birkbak NJ, Zaccaria S, Jamal-Hanjani M, McGranahan N, Swanton C |
Nature | 2023 |
|
Molecular portraits of lung cancer evolution.
Hayes TK, Meyerson M |
Nature | 2023 |
|
Chromosome-specific segment size alterations are determinants of prognosis in prostate cancer
Alfahed A, Ebili HO, Waggiallah HA |
Saudi Journal of Biological Sciences | 2023 |
|
Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
Kobelyatskaya AA, Pudova EA, Katunina IV, Snezhkina AV, Fedorova MS, Pavlov VS, Kotelnikova AO, Nyushko KM, Alekseev BY, Krasnov GS, Kudryavtseva AV |
International journal of molecular sciences | 2023 |
|
Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A, Gandaglia G, de Angelis M, Fallara G, Mazzone E, Stabile A, Pellegrino F, Robesti D, Leni R, Scuderi S, Cucchiara V, Cirulli GO, Barletta F, Montorsi F, Briganti A |
World Journal of Urology | 2023 |
|
Single-Setting 3D MRI/US-Guided Frozen Sectioning and Cryoablation of the Index Lesion: Mid-Term Oncologic and Functional Outcomes from a Pilot Study
Misuraca L, Lugnani F, Brassetti A, Cacciatore L, Tedesco F, Anceschi U, Bove AM, D\u2019Annunzio S, Ferriero M, Guaglianone S, Mastroianni R, Tuderti G, Panebianco V, Sentinelli S, Simone G |
Journal of Personalized Medicine | 2023 |
|
Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
Hamdan D, Marisa L, Tlemsani C, Angeli E, Soussan M, Derive N, Laurent-Puig P, Bousquet G |
JCO Precision Oncology | 2023 |
|
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin CC, Wang SS, Bianchini D, Bailey M, Schlieker L, Bogenrieder T, de Bono J |
British Journal of Cancer | 2023 |
|
Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches
Xulu KR, Nweke EE, Augustine TN |
Frontiers in Genetics | 2023 |
|
Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated “Omics” Approaches to Explore Measurable Metrics
Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis AG, Soundararajan R, Tzelepi V |
Cancers | 2023 |
|
Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
Nurminen A, Jaatinen S, Taavitsainen S, Högnäs G, Lesluyes T, Ansari-Pour N, Tolonen T, Haase K, Koskenalho A, Kankainen M, Jasu J, Rauhala H, Kesäniemi J, Nikupaavola T, Kujala P, Rinta-Kiikka I, Riikonen J, Kaipia A, Murtola T, Tammela TL, Visakorpi T, Nykter M, Wedge DC, Van Loo P, Bova GS |
Genome Medicine | 2023 |
|
Lymph nodes: At the intersection of cancer treatment and progression
Reticker-Flynn NE, Engleman EG |
Trends in Cell Biology | 2023 |
|
From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine
Ren S, Li J, Dorado J, Sierra A, González-Díaz H, Duardo A, Shen B |
Health Information Science and Systems | 2023 |
|
Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer
Vlajnic T, Müller DC, Ruiz C, Schönegg R, Seifert H, Thalmann GN, Zellweger T, Le Magnen C, Rentsch CA, Bubendorf L |
EMBO reports | 2023 |
|
Health inequity drives disease biology to create disparities in prostate cancer outcomes
William Nelson, Otis Brawley, William Isaacs, Elizabeth Platz, Srinivasan Yegnasubramanian, Karen Sfanos, Tamara Lotan, Angelo De Marzo |
Journal of Clinical Investigation | 2022 |
|
Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis
W Zhang, T Wang, Y Wang, F Zhu, H Shi, J Zhang, Z Wang, M Qu, H Zhang, T Wang, Y Qian, J Yang, X Gao, J Li |
Translational oncology | 2022 |
|
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression
W Gesztes, C Schafer, D Young, J Fox, J Jiang, Y Chen, H Kuo, K Mwamukonda, A Dobi, A Burke, J Moul, D McLeod, I Rosner, G Petrovics, S Tan, J Cullen, S Srivastava, I Sesterhenn |
Scientific Reports | 2022 |
|
Genomic Characterization of De Novo Metastatic Breast Cancer
S Mullangi, N Vasan |
Clinical Breast Cancer | 2022 |
|
Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
W Zhang, Y Dong, O Sartor, K Zhang |
Cancer informatics | 2022 |
|
The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease
H AlGhamdi, J Dhont, M Krayem, P Bruyn, B Engels, D Gestel, R den Begin |
Cancers | 2022 |
|
Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GO, Bejnood A, Martins MM, Kenkel JA, Linde IL, Bagchi S, Yuan R, Chang S, Spitzer MH, Carmi Y, Cheng J, Tolentino LL, Choi O, Wu N, Kong C, Gentles AJ, Sunwoo JB, Satpathy AT, Plevritis SK, Engleman EG |
Cell | 2022 |
|
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A, True L, Nelson PS, Robinson BD, Mosquera JM, Tomlins SA, Shen R, Demichelis F, Rubin MA |
The Journal of Pathology | 2022 |
|
The evolving landscape of prostate cancer somatic mutations
Cotter K, Rubin MA |
The Prostate | 2022 |
|
Association of Tumor Size With Prognosis in Patients With Resectable Endometrial Cancer: A SEER Database Analysis.
Hou X, Yue S, Liu J, Qiu Z, Xie L, Huang X, Li S, Hu L, Wu J |
Frontiers in Oncology | 2022 |
|
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Kneppers J, Bergman AM, Zwart W |
Advances in experimental medicine and biology | 2022 |
|
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness.
Liu X, Li WJ, Puzanov I, Goodrich DW, Chatta G, Tang DG |
Essays in Biochemistry | 2022 |
|
Polyploid giant cancer cells and cancer progression
Zhou X, Zhou M, Zheng M, Tian S, Yang X, Ning Y, Li Y, Zhang S |
Frontiers in Cell and Developmental Biology | 2022 |
|
Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study.
Titze U, Sommerkamp J, Stege C, Schneider F, Brochhausen C, Schulz B, Titze B, Abd Ali F, Pokupic S, Sievert KD, Hansen T |
International journal of molecular sciences | 2022 |
|
Biology, vulnerabilities and clinical applications of circulating tumour cells
Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N |
Nature reviews. Cancer | 2022 |
|
Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer
Rzhevskiy AS, Kapitannikova AY, Butnaru DV, Shpot EV, Joosse SA, Zvyagin AV, Ebrahimi Warkiani M |
Biomedicines | 2022 |
|
Research progress of m6A methylation in prostate cancer
Zhang SY, Zeng Y |
Asian Journal of Andrology | 2022 |
|
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
W Nathaniel Brennen, Yezi Zhu, Ilsa Coleman, Susan Dalrymple, Lizamma Antony, Radhika A Patel, Brian Hanratty, Roshan Chikarmane, Alan Meeker, S. Lilly Zheng, Jody E. Hooper, Jun Luo, Angelo M De Marzo, Eva Corey, Jianfeng Xu, Srinivasan Yegnasubramanian, Michael C. Haffner, Peter Nelson, William G. Nelson, William B. Isaacs, John T Isaacs |
JCI Insight | 2021 |
|
Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
TM Severson, Y Zhu, AM Marzo, T Jones, JW Simons, WG Nelson, S Yegnasubramanian, ML Freedman, L Wessels, AM Bergman, MC Haffner, W Zwart |
Molecular Oncology | 2021 |
|
Transitional dynamics of cancer stem cells in invasion and metastasis
V Richard, TR Kumar, RM Pillai |
Translational oncology | 2021 |
|
Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
D Klusa, F Lohaus, G Furesi, M Rauner, M Benešová, M Krause, I Kurth, C Peitzsch |
Frontiers in Oncology | 2021 |
|
Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer
S Rashdan, P Iyengar, JD Minna, DE Gerber |
Translational Lung Cancer Research | 2021 |
|
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
L Brady, M Kriner, I Coleman, C Morrissey, M Roudier, LD True, R Gulati, SR Plymate, Z Zhou, B Birditt, R Meredith, G Geiss, M Hoang, J Beechem, PS Nelson |
Nature Communications | 2021 |
|
Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient
L Bresadola, D Weber, C Ritzel, M Löwer, V Bukur, Ö Akilli-Öztürk, J Becker, H Mehanna, B Schrörs, F Vascotto, U Sahin, A Kong |
International journal of molecular sciences | 2021 |
|
Cell Force-Driven Basement Membrane Disruption Fuels EGF- and Stiffness-Induced Invasive Cell Dissemination from Benign Breast Gland Acini
A Gaiko-Shcherbak, J Eschenbruch, NM Kronenberg, M Teske, B Wolters, R Springer, MC Gather, R Merkel, B Hoffmann, E Noetzel |
International journal of molecular sciences | 2021 |
|
Should Grade Group 1 (GG1) be called cancer?
CV Labbate, GP Paner, SE Eggener |
World Journal of Urology | 2021 |
|
High‐grade tumours promote growth of other less‐malignant tumours in the same prostate
SH Bergström, S Rudolfsson, M Lundholm, A Josefsson, P Wikström, A Bergh |
The Journal of Pathology | 2021 |
|
Harnessing non-destructive 3D pathology
JT Liu, AK Glaser, K Bera, LD True, NP Reder, KW Eliceiri, A Madabhushi |
Nature Biomedical Engineering | 2021 |
|
Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
F Gaiani, F Marchesi, F Negri, L Greco, A Malesci, GL deAngelis, L Laghi |
International journal of molecular sciences | 2021 |
|
Cell Biology and Translational Medicine, Volume 12: Stem Cells in Development and Disease
K Turksen |
2021 | |
|
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer
S Gupta, S Halabi, G Kemeny, M Anand, P Giannakakou, DM Nanus, DJ George, SG Gregory, AJ Armstrong |
Molecular cancer research : MCR | 2021 |
|
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA
MT Schweizer, S Sivakumar, H Tukachinsky, I Coleman, ND Sarkar, EY Yu, EQ Konnick, PS Nelson, CC Pritchard, B Montgomery |
JAMA Oncology | 2021 |
|
Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens
SA Harmon, W Gesztes, D Young, S Mehralivand, Y McKinney, T Sanford, J Sackett, J Cullen, IL Rosner, S Srivastava, MJ Merino, BJ Wood, PA Pinto, PL Choyke, A Dobi, IA Sesterhenn, B Turkbey |
Radiology | 2021 |
|
SLX4IP N‐terminus dictates telomeric localization in ALT‐like castration‐resistant prostate cancer cell lines
TL Mangosh, MM Grabowska, DJ Taylor |
The Prostate | 2021 |
|
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis
J Ma, M Cai, Y Mo, JS Fried, X Tan, Y Ma, J Chen, S Han, B Xu |
Frontiers in Oncology | 2021 |
|
Decoding the heterogeneous landscape in the development prostate cancer (Review)
Y Segura-Moreno, M Sanabria-Salas, R Varela, J Mesa, M Serrano |
Oncology Letters | 2021 |
|
Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study
X Guo, H Xia, X Su, H Hou, Q Zhong, J Wang |
Frontiers in Oncology | 2021 |
|
Diagnostic Performance of Ex Vivo Fluorescence Confocal Microscopy in the Assessment of Diagnostic Biopsies of the Prostate
U Titze, T Hansen, C Brochhausen, B Titze, B Schulz, A Gunnemann, B Rocco, KD Sievert |
Cancers | 2021 |
|
Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer
K Cheaito, H Bahmad, O Hadadeh, H Msheik, A Monzer, F Ballout, C Dagher, T Telvizian, N Saheb, A Tawil, M ElSabban, A ElHajj, D Mukherji, M AlSayegh, W Aboukheir |
Oncology Letters | 2021 |
|
Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses
S Kim, J Park, H Seo, M Kim, J Park, G Kim, J Lee, Y Shin, J Bae, B Koo, S Jeong, J Ku |
Advanced Science | 2021 |
|
Circulating tumor DNA profile recognizes transformation to castration resistant neuroendocrine prostate cancer
Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini, Francesco Orlando, Tarcisio Fedrizzi, Sheng-Yu Ku, Emma Dann, Alicia Alonso, Juan Miguel Mosquera, Andrea Sboner, Jenny Xiang, Olivier Elemento, David M. Nanus, Scott T Tagawa, Matteo Benelli, Francesca Demichelis |
Journal of Clinical Investigation | 2020 |
|
Accelerating precision medicine in metastatic prostate cancer
J Mateo, R McKay, W Abida, R Aggarwal, J Alumkal, A Alva, F Feng, X Gao, J Graff, M Hussain, F Karzai, B Montgomery, W Oh, V Patel, D Rathkopf, M Rettig, N Schultz, M Smith, D Solit, C Sternberg, EV Allen, D VanderWeele, J Vinson, HR Soule, A Chinnaiyan, E Small, JW Simons, W Dahut, AK Miyahira, H Beltran |
2020 | |
|
Genomic and phenotypic heterogeneity in prostate cancer
MC Haffner, W Zwart, MP Roudier, LD True, WG Nelson, JI Epstein, AM Marzo, PS Nelson, S Yegnasubramanian |
Nature Reviews Urology | 2020 |
|
Computational Detection of Breast Cancer Invasiveness with DNA Methylation Biomarkers
C Wang, N Zhao, L Yuan, X Liu |
Cells | 2020 |
|
Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate
CM Heaphy, MC Haffner, MK Graham, D Lim, C Davis, E Corey, JI Epstein, MA Eisenberger, H Wang, AM Marzo, AK Meeker, TL Lotan |
Human Pathology | 2020 |
|
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
RJ Bryant, J Oxley, GJ Young, JA Lane, C Metcalfe, M Davis, EL Turner, RM Martin, JR Goepel, M Varma, DF Griffiths, K Grigor, N Mayer, AY Warren, S Bhattarai, J Dormer, M Mason, J Staffurth, E Walsh, DJ Rosario, JW Catto, DE Neal, JL Donovan, FC Hamdy, P Bollina, A Doble, A Doherty, D Gillatt, V Gnanapragasam, O Hughes, R Kockelbergh, H Kynaston, A Paul, E Paez, E Rowe |
BJU International | 2020 |
|
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
FC Hamdy, JL Donovan, JA Lane, M Mason, C Metcalfe, P Holding, J Wade, S Noble, K Garfield, G Young, M Davis, TJ Peters, EL Turner, RM Martin, J Oxley, M Robinson, J Staffurth, E Walsh, J Blazeby, R Bryant, P Bollina, J Catto, A Doble, A Doherty, D Gillatt, V Gnanapragasam, O Hughes, R Kockelbergh, H Kynaston, A Paul, E Paez, P Powell, S Prescott, D Rosario, E Rowe, D Neal |
HEALTH TECHNOL ASSES | 2020 |
|
Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer
C Zamboglou, AS Bettermann, C Gratzke, M Mix, J Ruf, S Kiefer, CA Jilg, M Benndorf, S Spohn, TF Fassbender, P Bronsert, M Chen, H Guo, F Wang, X Qiu, AL Grosu |
European Journal of Nuclear Medicine and Molecular Imaging | 2020 |
|
Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
CD Goodman, H Fakir, S Pautler, J Chin, GS Bauman |
Advances in Radiation Oncology | 2020 |
|
Mitochondrial DNA analysis efficiently contributes to the identification of metastatic contralateral breast cancers
G Girolimetti, L Marchio, AD Leo, M Mangiarelli, LB Amato, S Zanotti, M Taffurelli, D Santini, G Gasparre, C Ceccarelli |
Journal of Cancer Research and Clinical Oncology | 2020 |
|
SLX4IP Promotes Telomere Maintenance in Androgen Receptor–Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization
TL Mangosh, WN Awadallah, MM Grabowska, DJ Taylor |
Molecular cancer research : MCR | 2020 |
|
Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases
JG Reiter, WT Hung, IH Lee, S Nagpal, P Giunta, S Degner, G Liu, EC Wassenaar, WR Jeck, MS Taylor, AA Farahani, HD Marble, S Knott, O Kranenburg, JK Lennerz, K Naxerova |
Nature Genetics | 2020 |
|
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, M Lock, GB Rodrigues, BP Yaremko, D Schellenberg, B Ahmad, S Senthi, A Swaminath, N Kopek, M Liu, K Moore, S Currie, R Schlijper, GS Bauman, J Laba, XM Qu, A Warner, S Senan |
Journal of Clinical Oncology | 2020 |
|
Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma
G Yuan, J Song, N Li, Q Song, Y Li, Y Du, X Wang, Y Jiao, L Wu |
Frontiers in Oncology | 2020 |
|
Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion
T Shiraishi, S Inui, Y Inoue, Y Saito, H Taga, M Kaneko, K Tsuji, S Ueda, T Ueda, T Matsugasumi, H Taniguchi, A Ueno, T Yamada, Y Yamada, T Iwata, A Fujihara, F Hongo, O Ukimura |
Scientific Reports | 2020 |
|
Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI
MJ Connor, MA Gorin, HU Ahmed, R Nigam |
Prostate Cancer and Prostatic Diseases | 2020 |
|
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
A Crippa, BD Laere, A Discacciati, B Larsson, JT Connor, EE Gabriel, C Thellenberg, E Jänes, G Enblad, A Ullen, M Hjälm-Eriksson, J Oldenburg, P Ost, J Lindberg, M Eklund, H Grönberg |
Trials | 2020 |
|
The Genetic Complexity of Prostate Cancer
E Compérat, G Wasinger, A Oszwald, R Kain, G Cancel-Tassin, O Cussenot |
Genes & development | 2020 |
|
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer
DR Wise, JA Schneider, J Armenia, VA Febles, B McLaughlin, R Brennan, KL Thoren, W Abida, KS Sfanos, AM Marzo, S Yegnasubramanian, JJ Fox, M Haas, H Heath, MH Kagey, W Newman, CA Sirard, M Fleisher, MJ Morris, Y Chen, SM Larson, MC Haffner, PS Nelson, N Schultz, MJ Garabedian, HI Scher, SK Logan, CL Sawyers |
JCO Precision Oncology | 2020 |
|
Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy
DJ Woodcock, E Riabchenko, S Taavitsainen, M Kankainen, G Gundem, DS Brewer, P Ellonen, M Lepistö, YA Golubeva, AC Warner, T Tolonen, J Jasu, WB Isaacs, MR Emmert-Buck, M Nykter, T Visakorpi, GS Bova, DC Wedge |
Nature Communications | 2020 |
|
Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model
J Linxweiler, T Hajili, C Körbel, C Berchem, P Zeuschner, A Müller, M Stöckle, MD Menger, K Junker, M Saar |
Scientific Reports | 2020 |
|
Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
I Kohaar, Q Li, Y Chen, L Ravindranath, D Young, A Ali, IA Sesterhenn, IL Rosner, J Cullen, S Srivastava, M Freedman, G Petrovics |
Oncotarget | 2020 |
|
Frequent Clonal Relations Between Metastases and Non-index Prostate Cancer Lesions
Jeroen Kneppers, Oscar Krijgsman, Monique Melis, Jeroen de Jong, Daniel Peeper, Elise Bekers, Henk van der Poel, Wilbert Zwart, Andries M Bergman |
JCI Insight | 2019 |
|
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy
Brian R Winters, Navonil De Sarkar, Sonali Arora, Hamid Bolouri, Sujata Jana, Funda Vakar-Lopez, Heather H Cheng, Michael Schweizer, Evan Yu, Petros Grivas, John K Lee, Lori Kollath, Sarah K Holt, Lisa McFerrin, Gavin Ha, Peter Nelson, Robert B. Montgomery, Jonathan Wright, HungMing Lam, Andrew C. Hsieh |
JCI Insight | 2019 |
|
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
U Testa, G Castelli, E Pelosi |
Medicines | 2019 |
|
A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
A Slaoui, S Albisinni, F Aoun, G Assenmacher, WA Obeid, R Diamand, S Regragui, A Touzani, A Bakar, A Mesfioui, T Karmouni, A Ameur, K Elkhader, A Koutani, A Ibnattya, T Roumeguere, A Peltier |
World Journal of Urology | 2019 |
|
Oligometastases in prostate cancer: Ablative treatment
A Palacios-Eito, A Béjar-Luque, M Rodríguez-Liñán, S García-Cabezas |
World journal of clinical oncology | 2019 |
|
A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens
RE Jimenez, TD Atwell, H Sicotte, B Eckloff, L Wang, P Barman, JP Sinnwell, PW Eiken, BP McMenomy, W Tan, L Wang, RE Carlson, M Kohli |
2019 | |
|
Engineering Multidimensional Evolutionary Forces to Combat Cancer
CE McCoach, TG Bivona |
Cancer Discovery | 2019 |
|
Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer
G Kothari, P Ost, P Cheung, P Blanchard, AC Tree, NJ van As, SS Lo, D Moghanaki, A Loblaw, S Siva |
Current Oncology Reports | 2019 |
|
Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor
MJ Hwang, KG Bryant, JH Seo, Q Liu, PA Humphrey, MA Melnick, DC Altieri, ME Robert |
The American Journal of Pathology | 2019 |
|
Identification of portal vein tumor thrombus with an independent clonal origin in hepatocellular carcinoma via multi-omics data analysis
L Shupeng, Z Zaixin, J Yin, X Jie, L Zhiyong, C Kai, C Shuqun, L Shanrong |
Cancer biology & medicine | 2019 |
|
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
ST Hennigan, SY Trostel, NT Terrigino, OS Voznesensky, RJ Schaefer, NC Whitlock, S Wilkinson, NV Carrabba, R Atway, S Shema, R Lake, AR Sweet, DJ Einstein, F Karzai, JL Gulley, P Chang, GJ Bubley, SP Balk, H Ye, AG Sowalsky |
JCO Precision Oncology | 2019 |
|
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
Y Yan, J Ma, D Wang, D Lin, X Pang, S Wang, Y Zhao, L Shi, H Xue, Y Pan, J Zhang, C Wahlestedt, FJ Giles, Y Chen, ME Gleave, CC Collins, D Ye, Y Wang, H Huang |
EMBO Molecular Medicine | 2019 |
|
Towards precision oncology in advanced prostate cancer
SY Ku, ME Gleave, H Beltran |
Nature Reviews Urology | 2019 |
|
Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
MK Graham, J Kim, J Da, JA Brosnan-Cashman, A Rizzo, JA Valle, L Chia, M Rubenstein, C Davis, Q Zheng, L Cope, M Considine, MC Haffner, AM Marzo, AK Meeker, CM Heaphy |
Molecular cancer research : MCR | 2019 |
|
GLUL Ablation Can Confer Drug Resistance to Cancer Cells via a Malate-Aspartate Shuttle-Mediated Mechanism
M Muthu, R Kumar, AS Khaja, JD Gilthorpe, JL Persson, A Nordström |
Cancers | 2019 |
|
Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer
SS Salami, JB Kaplan, S Nallandhighal, M Takhar, JJ Tosoian, M Lee, J Yoon, DH Hovelson, KR Plouffe, SD Kaffenberger, EM Schaeffer, RJ Karnes, TL Lotan, TM Morgan, AK George, JS Montgomery, MS Davenport, S You, SA Tomlins, NE Curci, HL Kim, DE Spratt, AM Udager, GS Palapattu |
JCO Precision Oncology | 2019 |
|
A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
T Kosaka, H Hongo, E Aimono, K Matsumoto, T Hayashida, S Mikami, H Nishihara, M Oya |
Pathology International | 2019 |
|
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
M Valeriani, L Marinelli, S Macrini, C Reverberi, AM Aschelter, VD Sanctis, P Marchetti, L Tronnolone, MF Osti |
Radiation Oncology | 2019 |
|
MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL)
F Fischbach, P Hass, D Schindele, P Genseke, L Geisendorf, C Stehning, M Schostak, T Brunner, M Pech, K Fischbach |
European Radiology | 2019 |
|
Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance
SR Amend, G Torga, KC Lin, LG Kostecka, A Marzo, RH Austin, KJ Pienta |
The Prostate | 2019 |
|
Transcriptional regulators and regulatory pathways involved in prostate gland adaptation to a hypoandrogen environment
U Nishan, R da Rosa-Ribeiro, DM Damas-Souza, GO Barbosa, HF Carvalho |
Genetics and molecular biology | 2019 |
|
If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease
KS Sfanos, S Yegnasubramanian, WG Nelson, TL Lotan, I Kulac, JL Hicks, Q Zheng, CJ Bieberich, MC Haffner, AM Marzo |
Asian Journal of Urology | 2019 |
|
Genomics applied to the treatment of breast cancer.
Hamdan D, Nguyen TT, Leboeuf C, Meles S, Janin A, Bousquet G |
Oncotarget | 2019 |
|
Genetics and biology of prostate cancer
G Wang, D Zhao, DJ Spring, RA DePinho |
Genes & development | 2018 |
|
Recent Advances in Prostate Cancer Treatment and Drug Discovery
E Nevedomskaya, S Baumgart, B Haendler |
International journal of molecular sciences | 2018 |
|
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
KH Jansson, JB Tucker, LE Stahl, JK Simmons, C Fuller, ML Beshiri, S Agarwal, L Fang, PG Hynes, AN Alilin, R Lake, YC Abbey, J Cawley, CM Tice, JJ Yin, C McKnight, C Klummp-Thomas, X Zhang, R Guha, S Hoover, RM Simpson, HM Nguyen, E Corey, CJ Thomas, DA Proia, K Kelly |
Scientific Reports | 2018 |
|
The Genomics of Prostate Cancer: A Historic Perspective
MA Rubin, F Demichelis |
Cold Spring Harbor Perspectives in Medicine | 2018 |
|
Overview on Clinical Relevance of Intra-Tumor Heterogeneity
G Stanta, S Bonin |
Frontiers in Medicine | 2018 |
|
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers
T Guo, L Li, Q Zhong, NJ Rupp, K Charmpi, CE Wong, U Wagner, JH Rueschoff, W Jochum, CD Fankhauser, K Saba, C Poyet, PJ Wild, R Aebersold, A Beyer |
2018 | |
|
Somatic mutations and increased lymphangiogenesis observed in a rare case of intramucosal gastric carcinoma with lymph node metastasis
N Ikari, S Aoyama, A Seshimo, Y Suehiro, T Motohashi, S Mitani, S Yoshina, E Tanji, A Serizawa, T Yamada, K Taniguchi, M Yamamoto, T Furukawa |
Oncotarget | 2018 |
|
Clinical implications of PTEN loss in prostate cancer
T Jamaspishvili, DM Berman, AE Ross, HI Scher, AM Marzo, JA Squire, TL Lotan |
Nature Reviews Urology | 2018 |
|
Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
S Aufderklamm, J Hennenlotter, P Leidenberger, S Rausch, A Hohneder, U Kühs, M Maas, C Schwentner, J Bedke, A Stenzl, T Todenhöfer |
Disease Markers | 2018 |
|
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, T OBrien, J Larkin, S Horswell, M Stares, L Au, M Jamal-Hanjani, B Challacombe, A Chandra, S Hazell, C Eichler-Jonsson, A Soultati, S Chowdhury, S Rudman, J Lynch, A Fernando, G Stamp, E Nye, F Jabbar, L Spain, S Lall, R Guarch, M Falzon, I Proctor, L Pickering, M Gore, TB Watkins, S Ward, A Stewart, R DiNatale, MF Becerra, E Reznik, JJ Hsieh, TA Richmond, GF Mayhew, SM Hill, CD McNally, C Jones, H Rosenbaum, S Stanislaw, DL Burgess, NR Alexander, C Swanton |
Cell | 2018 |
|
Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI
RS Pompe, B Kühn-Thomä, Y Nagaraj, V Veleva, F Preisser, SR Leyh-Bannurah, M Graefen, H Huland, D Tilki, G Salomon |
World Journal of Urology | 2018 |
|
Towards a universal MRI atlas of the prostate and prostate zones: Comparison of MRI vendor and image acquisition parameters
KR Padgett, A Swallen, S Pirozzi, J Piper, FM Chinea, MC Abramowitz, A Nelson, A Pollack, R Stoyanova |
Strahlentherapie und Onkologie | 2018 |
|
Ablation energies for focal treatment of prostate cancer
O Lodeizen, M de Bruin, S Eggener, S Crouzet, S Ghai, I Varkarakis, A Katz, JL Dominguez-Escrig, S Pahernik, T de Reijke, J de la Rosette |
World Journal of Urology | 2018 |
|
Cancer evolution and heterogeneity
K Mimori, T Saito, A Niida, S Miyano |
Annals of Gastroenterological Surgery | 2018 |
|
A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer
T Saito, A Niida, R Uchi, H Hirata, H Komatsu, S Sakimura, S Hayashi, S Nambara, Y Kuroda, S Ito, H Eguchi, T Masuda, K Sugimachi, T Tobo, H Nishida, T Daa, K Chiba, Y Shiraishi, T Yoshizato, M Kodama, T Okimoto, K Mizukami, R Ogawa, K Okamoto, M Shuto, K Fukuda, Y Matsui, T Shimamura, T Hasegawa, Y Doki, S Nagayama, K Yamada, M Kato, T Shibata, M Mori, H Aburatani, K Murakami, Y Suzuki, S Ogawa, S Miyano, K Mimori |
Nature Communications | 2018 |
|
Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review
KC Koo, P Dasgupta |
Yonsei Medical Journal | 2018 |
|
Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling
A Niida, S Nagayama, S Miyano, K Mimori |
Cancer Science | 2018 |
|
The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
C Zamboglou, CM Klein, B Thomann, TF Fassbender, HC Rischke, S Kirste, K Henne, N Volegova-Neher, M Bock, M Langer, PT Meyer, D Baltas, AL Grosu |
Radiation Oncology | 2018 |
|
Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy
N Nassiri, E Chang, P Lieu, AM Priester, DJ Margolis, J Huang, RE Reiter, FJ Dorey, LS Marks, S Natarajan |
The Journal of Urology | 2018 |
|
An ex vivo Tissue Culture Model for the Assessment of Individualized Drug Responses in Prostate and Bladder Cancer
AF van de Merbel, G van der Horst, MH van der Mark, JI van Uhm, EJ van Gennep, P Kloen, L Beimers, RC Pelger, G van der Pluijm |
Frontiers in Oncology | 2018 |
|
Multimodal imaging for radiation therapy planning in patients with primary prostate cancer
C Zamboglou, M Eiber, TR Fassbender, M Eder, S Kirste, M Bock, O Schilling, K Reichel, UA van der Heide, AL Grosu |
2018 | |
|
Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation
RD Singh, R Shandilya, A Bhargava, R Kumar, R Tiwari, K Chaudhury, RK Srivastava, IY Goryacheva, PK Mishra |
Frontiers in Genetics | 2018 |
|
Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases
L Schmidt, M Møller, C Haldrup, SH Strand, S Vang, J Hedegaard, S Høyer, M Borre, T Ørntoft, KD Sørensen |
British Journal of Cancer | 2018 |
|
Metastases in Prostate Cancer
FL Manna, S Karkampouna, E Zoni, MD Menna, J Hensel, GN Thalmann, MK Julio |
Cold Spring Harbor Perspectives in Medicine | 2018 |
|
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications
S Yegnasubramanian, AM Marzo, WG Nelson |
Cold Spring Harbor Perspectives in Medicine | 2018 |
|
Functional roles of Speckle-Type Poz (SPOP) Protein in Genomic stability
, J Fried, Y Li, L Hu, M Gao, S Zhang, B Xu |
Journal of Cancer | 2018 |
|
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
M Riedel, MF Berthelsen, L Bakiri, EF Wagner, MK Thomsen |
Journal of visualized experiments : JoVE | 2018 |
|
Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient
K Prado, KX Zhang, M Pellegrini, AI Chin |
Oncotarget | 2017 |
|
Telomeres and telomerase in prostate cancer development and therapy
MK Graham, A Meeker |
Nature Reviews Urology | 2017 |
|
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein
C Geng, S Kaochar, M Li, K Rajapakshe, W Fiskus, J Dong, C Foley, B Dong, L Zhang, OJ Kwon, SS Shah, M Bolaki, L Xin, M Ittmann, BW O'Malley, C Coarfa, N Mitsiades |
Oncogene | 2017 |
|
Emerging Biological Principles of Metastasis
AW Lambert, DR Pattabiraman, RA Weinberg |
Cell | 2017 |
|
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report
N Valtcheva, FM Lang, A Noske, EP Samartzis, AM Schmidt, E Bellini, D Fink, H Moch, M Rechsteiner, KJ Dedes, PJ Wild |
BMC Cancer | 2017 |
|
Identifying aggressive prostate cancer foci using a DNA methylation classifier
K Mundbjerg, S Chopra, M Alemozaffar, C Duymich, R Lakshminarasimhan, PW Nichols, M Aron, KD Siegmund, O Ukimura, M Aron, M Stern, P Gill, JD Carpten, TF Ørntoft, KD Sørensen, DJ Weisenberger, PA Jones, V Duddalwar, I Gill, G Liang |
Genome biology | 2017 |
|
A population genetics perspective on the determinants of intra-tumor heterogeneity
Z Hu, R Sun, C Curtis |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2017 |
|
Die radikale Prostatektomie als Teil eines multimodalen Konzepts für Patienten mit Prostatakarzinom- und Knochenmetastasen bei der Erstdiagnose
A Spek, A Herlemann, C Gratzke, CG Stief |
Der Urologe, Ausgabe A | 2017 |
|
Wann ist bei eingetretener Metastasierung des Prostatakarzinoms die operative Entfernung des Primärtumors angezeigt und gibt es eine wissenschaftliche Grundlage dafür?
J Noldus |
Der Urologe, Ausgabe A | 2017 |
|
Cancer metastasis: enactment of the script for human reproductive drama
X Sun, X Liu |
Cancer Cell International | 2017 |
|
Hat Active Surveillance beim Prostatakarzinom noch einen Stellenwert?
M Stöckle |
Der Urologe, Ausgabe A | 2017 |
|
Tumour heterogeneity poses a significant challenge to cancer biomarker research
K Cyll, E Ersvær, L Vlatkovic, M Pradhan, W Kildal, MA Kjær, A Kleppe, TS Hveem, B Carlsen, S Gill, S Löffeler, ES Haug, H Wæhre, P Sooriakumaran, HE Danielsen |
British Journal of Cancer | 2017 |
|
Origins of lymphatic and distant metastases in human colorectal cancer
K Naxerova, JG Reiter, E Brachtel, JK Lennerz, M de Wetering, A Rowan, T Cai, H Clevers, C Swanton, MA Nowak, SJ Elledge, RK Jain |
Science | 2017 |
|
Die zytoreduktive radikale Prostatektomie beim metastasierten Prostatakarzinom
M Chaloupka, A Herlemann, A Spek, C Gratzke, C Stief |
Der Urologe, Ausgabe A | 2017 |
|
Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer
MB Thomsen, I Nordentoft, P Lamy, S Vang, L Reinert, CK Mapendano, S Høyer, TF Ørntoft, JB Jensen, L Dyrskjøt |
Scientific Reports | 2017 |
|
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer
J Kim, JS Park, WS Ham |
Investigative and Clinical Urology | 2017 |
|
A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer
S Liu, S Kumari, Q Hu, D Senapati, VB Venkadakrishnan, D Wang, AD DePriest, SE Schlanger, S Ben-Salem, MM Valenzuela, B Willard, S Mudambi, WM Swetzig, GM Das, M Shourideh, S Koochekpour, SM Falzarano, C Magi-Galluzzi, N Yadav, X Chen, C Lao, J Wang, JN Billaud, HV Heemers |
eLife | 2017 |
|
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors
A Albitar, W Ma, I DeDios, J Estella, I Ahn, M Farooqui, A Wiestner, M Albitar |
Oncotarget | 2017 |
|
Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
LB Guedes, F Almutairi, MC Haffner, G Rajoria, Z Liu, S Klimek, R Zoino, K Yousefi, R Sharma, AM de Marzo, GJ Netto, WB Isaacs, AE Ross, EM Schaeffer, TL Lotan |
Clinical cancer research | 2017 |
|
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling
M Blattner, D Liu, BD Robinson, D Huang, A Poliakov, D Gao, S Nataraj, LD Deonarine, MA Augello, V Sailer, L Ponnala, M Ittmann, AM Chinnaiyan, A Sboner, Y Chen, MA Rubin, CE Barbieri |
Cancer Cell | 2017 |
|
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4
AG Sowalsky, HT Kissick, SJ Gerrin, RJ Schaefer, Z Xia, JW Russo, MS Arredouani, GJ Bubley, MG Sanda, W Li, H Ye, SP Balk |
Clinical cancer research | 2017 |
|
Comparison of 68 Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
C Zamboglou, V Drendel, CA Jilg, HC Rischke, TI Beck, W Schultze-Seemann, T Krauss, M Mix, F Schiller, U Wetterauer, M Werner, M Langer, M Bock, PT Meyer, AL Grosu |
Theranostics | 2017 |
|
Metabolomics Applications in Precision Medicine: An Oncological Perspective
L Puchades-Carrasco, AP Lucena |
Current topics in medicinal chemistry | 2017 |
|
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer
K Lefort, P Ostano, M Mello-Grand, V Calpini, M Scatolini, A Farsetti, GP Dotto, G Chiorino |
Oncotarget | 2016 |
|
Translational and clinical implications of the genetic landscape of prostate cancer
DE Spratt, ZS Zumsteg, FY Feng, SA Tomlins |
Nature Reviews Clinical Oncology | 2016 |
|
Clonal origin and spread of metastatic prostate cancer
JL van Etten, SM Dehm |
Endocrine Related Cancer | 2016 |
|
Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
LB Guedes, CL Morais, F Almutairi, MC Haffner, Q Zheng, JT Isaacs, ES Antonarakis, C Lu, H Tsai, J Luo, AM de Marzo, TL Lotan |
Clinical cancer research | 2016 |
|
Tumour heterogeneity: principles and practical consequences
G Stanta, SW Jahn, S Bonin, G Hoefler |
Virchows Archiv | 2016 |
|
Clonal cooperativity in heterogenous cancers
H Zhou, D Neelakantan, HL Ford |
Seminars in Cell & Developmental Biology | 2016 |
|
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, H Bolouri, B Montgomery, T White, JM Lucas, LG Brown, RF Dumpit, N DeSarkar, C Higano, EY Yu, R Coleman, N Schultz, M Fang, PH Lange, J Shendure, RL Vessella, PS Nelson |
Nature Medicine | 2016 |
|
Single punch, double biopsy
M Krönig, N Nanko, V Drendel, M Werner, W Schultze-Seemann, AL Grosu, AC Jilg |
SpringerPlus | 2016 |
|
Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort
S Loeb, Y Folkvaljon, D Robinson, IF Lissbrant, L Egevad, P Stattin |
European Urology | 2016 |
|
Prostatakarzinom: Teil 1: Rückblick über Zellkinetik der Jahre 1966–2015 und Zukunftsperspektiven des neuen Gradings der International Society of Urological Pathology (ISUP)
B Helpap, L Bubendorf |
Der Pathologe | 2016 |
|
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer: Intratumoral Heterogeneity in NSGCT
SM Tu, MA Bilen, KR Hess, RR Broaddus, S Kopetz, C Wei, LC Pagliaro, JA Karam, JF Ward, CG Wood, P Rao, ZH Tu, R General, AH Chen, YL Nieto, SJ Yeung, SH Lin, CJ Logothetis, LL Pisters |
Cancer | 2016 |
|
Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?
R Rosset, F Bratan, S Crouzet, H Tonoli-Catez, F Mège-Lechevallier, A Gelet, O Rouvière |
European Radiology | 2016 |
|
Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer
L Wang, J Wang, H Xiong, F Wu, T Lan, Y Zhang, X Guo, H Wang, M Saleem, C Jiang, J Lu, Y Deng |
EBioMedicine | 2016 |
|
Fokale Therapie des Prostatakarzinoms in Deutschland
M Apfelbeck, A Herlemann, CG Stief, C Gratzke |
Der Urologe, Ausgabe A | 2016 |
|
Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens
BS Knudsen, HL Kim, N Erho, H Shin, M Alshalalfa, LL Lam, I Tenggara, K Chadwich, TV der Kwast, N Fleshner, E Davicioni, PR Carroll, MR Cooperberg, JM Chan, JP Simko |
The Journal of Molecular Diagnostics | 2016 |
|
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
KA Lipinski, LJ Barber, MN Davies, M Ashenden, A Sottoriva, M Gerlinger |
Trends in Cancer | 2016 |
|
Aktive Überwachung beim Niedrig-Risiko-Prostatakarzinom
A Herlemann, CG Stief |
Der Urologe, Ausgabe A | 2016 |
|
Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
M Bartucci, AC Ferrari, IY Kim, A Ploss, M Yarmush, HE Sabaawy |
Frontiers in Cell and Developmental Biology | 2016 |
|
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators
L Wei, J Wang, E Lampert, S Schlanger, AD DePriest, Q Hu, EC Gomez, M Murakam, ST Glenn, J Conroy, C Morrison, G Azabdaftari, JL Mohler, S Liu, HV Heemers |
European Urology | 2016 |
|
Does true Gleason pattern 3 merit its cancer descriptor?
S Miah, HU Ahmed, A Freeman, M Emberton |
Nature Reviews Urology | 2016 |
|
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
M Moschini, M Spahn, A Mattei, J Cheville, RJ Karnes |
BMC Medicine | 2016 |
|
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity
Q Zhong, JH Rüschoff, T Guo, M Gabrani, PJ Schüffler, M Rechsteiner, Y Liu, TJ Fuchs, NJ Rupp, C Fankhauser, JM Buhmann, S Perner, C Poyet, M Blattner, D Soldini, H Moch, MA Rubin, A Noske, J Rüschoff, MC Haffner, W Jochum, PJ Wild |
Scientific Reports | 2016 |
|
Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies
N Sheikh, C Wei, M Szewczyk-Bieda, A Campbell, S Memon, S Lang, G Nabi |
World Journal of Urology | 2016 |
|
68 Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison
C Zamboglou, F Schiller, T Fechter, G Wieser, CA Jilg, A Chirindel, N Salman, V Drendel, M Werner, M Mix, PT Meyer, AL Grosu |
Theranostics | 2016 |
|
Prostate cancer epigenetics and its clinical implications
S Yegnasubramanian |
Asian Journal of Andrology | 2016 |
|
Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer
GS Bova, HM Kallio, M Annala, K Kivinummi, G Högnäs, S Häyrynen, T Rantapero, V Kivinen, WB Isaacs, T Tolonen, M Nykter, T Visakorpi |
Molecular Case Studies | 2016 |
|
Clinical variability and molecular heterogeneity in prostate cancer
J Shoag, CE Barbieri |
Asian Journal of Andrology | 2016 |
|
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer
W Liu |
Asian Journal of Andrology | 2016 |
|
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, C Massard, C Lévy, M Arnedos, M Lacroix-Triki, J Garrabey, Y Boursin, M Deloger, Y Fu, F Commo, V Scott, L Lacroix, MV Dieci, M Kamal, V Diéras, A Gonçalves, JM Ferrerro, G Romieu, L Vanlemmens, MA Reynier, JC Théry, FL Du, S Guiu, F Dalenc, G Clapisson, H Bonnefoi, M Jimenez, CL Tourneau, F André, ER Mardis |
PLoS Medicine | 2016 |
|
The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment:
DH Hovelson, SA Tomlins |
The Cancer Journal | 2016 |
|
miRNA-21 as a novel therapeutic target in lung cancer
E Lianidou, A Markou, M Zavridou |
Lung Cancer: Targets and Therapy | 2016 |
|
Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
GS Palapattu, SS Salami, AK Cani, DH Hovelson, LL de la Vega, KR Vandenberg, JV Bratley, CJ Liu, LP Kunju, JS Montgomery, TM Morgan, S Natarajan, J Huang, SA Tomlins, LS Marks |
Clinical cancer research | 2016 |
|
Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies
R Stoyanova, A Pollack, M Takhar, C Lynne, N Parra, LL Lam, M Alshalalfa, C Buerki, R Castillo, M Jorda, HA Ashab, ON Kryvenko, S Punnen, DJ Parekh, MC Abramowitz, RJ Gillies, E Davicioni, N Erho, A Ishkanian |
Oncotarget | 2016 |
|
A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study
P Castelo-Branco, R Leão, T Lipman, B Campbell, D Lee, A Price, C Zhang, A Heidari, D Stephens, S Boerno, H Coelho, A Gomes, C Domingos, JD Apolonio, G Schäfer, RG Bristow, MR Schweiger, R Hamilton, A Zlotta, A Figueiredo, H Klocker, H Sültmann, U Tabori |
Oncotarget | 2016 |
|
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
A Brouwer, BD Laere, D Peeters, M Peeters, R Salgado, L Dirix, SV Laere |
Oncotarget | 2016 |
|
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications
Q Deng, DG Tang |
Endocrine Related Cancer | 2015 |
|
Clinical management of breast cancer heterogeneity
D Zardavas, A Irrthum, C Swanton, M Piccart |
Nature Reviews Clinical Oncology | 2015 |
|
Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome
H Cho, T Herzka, C Stahlhut, K Watrud, BD Robinson, LC Trotman |
Methods | 2015 |
|
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
GK Hubbard, LN Mutton, M Khalili, RP McMullin, JL Hicks, D Bianchi-Frias, LA Horn, I Kulac, MS Moubarek, PS Nelson, S Yegnasubramanian, AM de Marzo, CJ Bieberich |
Cancer research | 2015 |
|
Rewired metabolism in drug-resistant leukemia cells: A metabolic switch hallmarked by reduced dependence on exogenous glutamine
C Stäubert, H Bhuiyan, A Lindahl, OJ Broom, Y Zhu, S Islam, S Linnarsson, J Lehtiö, A Nordström |
The Journal of biological chemistry | 2015 |
|
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
LJ Barber, MN Davies, M Gerlinger |
Current Opinion in Genetics & Development | 2015 |
|
Active Surveillance for Low-Risk Prostate Cancer
L Klotz |
Current Urology Reports | 2015 |
|
Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate: Novel In Vivo Model for Combinatorial Fluorescence Labeling
X Fang, K Gyabaah, B Nickkholgh, JM Cline, KC Balaji |
The Prostate | 2015 |
|
Using tumour phylogenetics to identify the roots of metastasis in humans
K Naxerova, RK Jain |
Nature Reviews Clinical Oncology | 2015 |
|
Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?
S Loeb, F Montorsi, JW Catto |
European Urology | 2015 |
|
Organ-Confined Prostate Cancer: Are We Moving Towards More or Less Radical Surgical Intervention?
DJ Stevens, NL Sharma, AK Tewari, R Kirby, P Sooriakumaran |
Current Urology Reports | 2015 |
|
Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting
IA Donaldson, R Alonzi, D Barratt, E Barret, V Berge, S Bott, D Bottomley, S Eggener, B Ehdaie, M Emberton, R Hindley, T Leslie, A Miners, N McCartan, CM Moore, P Pinto, TJ Polascik, L Simmons, J der Meulen, A Villers, S Willis, HU Ahmed |
European Urology | 2015 |
|
Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer
KR Leite, ST Reis, N Viana, DR Morais, CM Moura, IA Silva, J Pontes, B Katz, M Srougi |
Journal of Cancer | 2015 |
|
Should Gleason 6 be labeled as cancer?:
I Kulac, MC Haffner, S Yegnasubramanian, JI Epstein, AM de Marzo |
Current Opinion in Urology | 2015 |
|
Translational Implications of Tumor Heterogeneity
M Jamal-Hanjani, SA Quezada, J Larkin, C Swanton |
Clinical cancer research | 2015 |
|
Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy
C Ibeawuchi, H Schmidt, R Voss, U Titze, M Abbas, J Neumann, E Eltze, A Hoogland, G Jenster, B Brandt, A Semjonow |
International journal of molecular sciences | 2015 |
|
Current Trends and New Frontiers in Focal Therapy for Localized Prostate Cancer
MH Mendez, DY Joh, R Gupta, TJ Polascik |
Current Urology Reports | 2015 |
|
Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes
SA Tomlins, M Alshalalfa, E Davicioni, N Erho, K Yousefi, S Zhao, Z Haddad, RB Den, AP Dicker, BJ Trock, AM DeMarzo, AE Ross, EM Schaeffer, EA Klein, C Magi-Galluzzi, RJ Karnes, RB Jenkins, FY Feng |
European Urology | 2015 |
|
Histological outcomes after focal high-intensity focused ultrasound and cryotherapy
TT Shah, V Kasivisvanathan, C Jameson, A Freeman, M Emberton, HU Ahmed |
World Journal of Urology | 2015 |
|
Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer
R Renard-Penna, G Cancel-Tassin, E Comperat, M Roupret, P Mozer, O Cussenot |
World Journal of Urology | 2015 |
|
A Human Fetal Prostate Xenograft Model of Developmental Estrogenization
CM Saffarini, EV McDonnell-Clark, A Amin, K Boekelheide |
International Journal of Toxicology | 2015 |
|
Prostate cancer: Intrapatient heterogeneity in prostate cancer
H Beltran, F Demichelis |
Nature Reviews Urology | 2015 |
|
Evaluation of the ‘Prostate Interdisciplinary Communication and Mapping Algorithm for Biopsy and Pathology’ (PIC-MABP)
D Junker, TR Herrmann, M Bader, J Bektic, G Henkel, S Kruck, M Sandbichler, D Schilling, G Schäfer, U Nagele |
World Journal of Urology | 2015 |
|
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
H der Poel, L Klotz, G Andriole, AR Azzouzi, A Bjartell, O Cussenot, F Hamdy, M Graefen, P Palma, AR Rivera, CG Stief |
World Journal of Urology | 2015 |
|
The role of individual inheritance in tumor progression and metastasis
K Hunter |
Journal of Molecular Medicine | 2015 |
|
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
C Swanton, N McGranahan, GJ Starrett, RS Harris |
Cancer Discovery | 2015 |
|
What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
M Spahn, S Boxler, S Joniau, M Moschini, B Tombal, RJ Karnes |
Current Urology Reports | 2015 |
|
How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity
PC Rida, G Cantuaria, MD Reid, O Kucuk, R Aneja |
Cancer and Metastasis Reviews | 2015 |
|
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer
AJ Armstrong, P Healy, S Halabi, R Vollmer, A Lark, G Kemeny, K Ware, SJ Freedland |
Prostate Cancer and Prostatic Diseases | 2015 |
|
Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization: Clonal origin of HGPIN
MC Haffner, C Weier, MM Xu, A Vaghasia, B Gürel, B Gümüşkaya, DM Esopi, H Fedor, HL Tan, I Kulac, J Hicks, WB Isaacs, TL Lotan, WG Nelson, S Yegnasubramanian, AM de Marzo |
The Journal of Pathology | 2015 |
|
Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment
KC Kadakia, SA Tomlins, SK Sanghvi, AK Cani, K Omata, DH Hovelson, CJ Liu, KA Cooney |
Journal of Hematology & Oncology | 2015 |
|
Clonotyping for precision oncology
HX Dang, CA Maher |
Drug Discovery Today | 2015 |
|
Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells
C Stäubert, R Krakowsky, H Bhuiyan, B Witek, A Lindahl, O Broom, A Nordström |
Medical Oncology | 2015 |
|
HDAC inhibition impedes epithelial–mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer
M Ruscetti, EL Dadashian, W Guo, B Quach, DJ Mulholland, JW Park, LM Tran, N Kobayashi, D Bianchi-Frias, Y Xing, PS Nelson, H Wu |
Oncogene | 2015 |
|
Cell line modeling to study biomarker panel in prostate cancer: Prostate Cancer Cell Line Modeling
B NickKholgh, X Fang, SM Winters, A Raina, KS Pandya, K Gyabaah, N Fino, KC Balaji |
The Prostate | 2015 |
|
A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer
R Velthoven, F Aoun, Q Marcelis, S Albisinni, M Zanaty, M Lemort, A Peltier, K Limani |
Prostate Cancer and Prostatic Diseases | 2015 |
|
Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma
Bousquet G, Bouchtaoui ME, Leboeuf C, Battistella M, Varna M, Ferreira I, Plassa LF, Hamdan D, Bertheau P, Feugeas JP, Damotte D, Janin A |
Oncotarget | 2015 |
|
The biology and treatment of oligometastatic cancer.
Reyes DK, Pienta KJ |
Oncotarget | 2015 |
|
Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.
Park CK, Park I, Lee S, Sun CH, Koh Y, Park SH, Kim JE, Yun H, Lee SH |
Oncotarget | 2015 |
|
A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM |
Oncotarget | 2015 |
|
Wie entwickeln sich Metastasen urologischer Tumoren?
M Rose, R Knüchel |
Der Urologe, Ausgabe A | 2014 |
|
Individualized Medicine from Prewomb to Tomb
EJ Topol |
Cell | 2014 |
|
Management of low risk prostate cancer—active surveillance and focal therapy
L Klotz, M Emberton |
Nature Reviews Clinical Oncology | 2014 |
|
Cancer evolution: the final frontier of precision medicine?
C Swanton |
Annals of Oncology | 2014 |
|
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines
L Spans, C Helsen, L Clinckemalie, TV Broeck, S Prekovic, S Joniau, E Lerut, F Claessens |
PloS one | 2014 |
|
Tumor clone dynamics in lethal prostate cancer
S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, D Prandi, D Lorente, JS Frenel, C Pezaro, A Omlin, DN Rodrigues, P Flohr, N Tunariu, JS de Bono, F Demichelis, G Attard |
Science Translational Medicine | 2014 |
|
One patient, two lesions, two oncogenic drivers of gastric cancer
C Alsinet, M Ranzani, DJ Adams |
Genome biology | 2014 |
|
Biopsie der Prostata: Update zu Indikation, Durchführung und zukünftiger Entwicklung
S Machtens, A Roosen, CG Stief, MC Truß |
Der Urologe, Ausgabe A | 2014 |
|
Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth
L Wang, H Xiong, F Wu, Y Zhang, J Wang, L Zhao, X Guo, LJ Chang, Y Zhang, MJ You, S Koochekpour, M Saleem, H Huang, J Lu, Y Deng |
Cell Reports | 2014 |
|
Das Niedrigrisikoprostatakarzinom
CG Stief, A Roosen |
Der Urologe, Ausgabe A | 2014 |
|
The emerging role of speckle-type POZ protein (SPOP) in cancer development
RS Mani |
Drug Discovery Today | 2014 |
|
High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
TD Rachner, S Thiele, A Göbel, A Browne, S Fuessel, K Erdmann, MP Wirth, M Fröhner, T Todenhöfer, MH Muders, M Kieslinger, M Rauner, LC Hofbauer |
BMC Cancer | 2014 |
|
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study
M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, G Middleton, E Bruin, JL Quesne, S Shafi, M Falzon, S Horswell, F Blackhall, I Khan, S Janes, M Nicolson, D Lawrence, M Forster, D Fennell, SM Lee, J Lester, K Kerr, S Muller, N Iles, S Smith, N Murugaesu, R Mitter, M Salm, A Stuart, N Matthews, H Adams, T Ahmad, R Attanoos, J Bennett, NJ Birkbak, R Booton, G Brady, K Buchan, A Capitano, M Chetty, M Cobbold, P Crosbie, H Davies, A Denison, M Djearman, J Goldman, T Haswell, L Joseph, M Kornaszewska, M Krebs, G Langman, M MacKenzie, J Millar, B Morgan, B Naidu, D Nonaka, K Peggs, C Pritchard, H Remmen, A Rowan, R Shah, E Smith, Y Summers, M Taylor, S Veeriah, D Waller, B Wilcox, M Wilcox, I Woolhouse, N McGranahan, C Swanton |
PLoS Biology | 2014 |
|
Loss of JUNB/AP-1 promotes invasive prostate cancer
MK Thomsen, L Bakiri, SC Hasenfuss, H Wu, M Morente, EF Wagner |
Cell Death and Differentiation | 2014 |
|
Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?
R Montironi, M Scarpelli, R Mazzucchelli, A Lopez-Beltran, M Santoni, A Briganti, F Montorsi, L Cheng |
Diagnostic Pathology | 2014 |
|
A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and/or the Metastases in Metastatic Prostate Cancer
F Aoun, A Peltier, R Velthoven |
BioMed Research International | 2014 |
|
Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options
AJ Moreno, CF Albiach, RM Soria, VG Vidal, RG Gómez, MA Antequera |
Radiation Oncology | 2014 |
|
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
I Faiena, E Singer, C Pumill, I Kim |
International journal of oncology | 2014 |
|
Tumour heterogeneity and the evolution of polyclonal drug resistance
RA Burrell, C Swanton |
Molecular Oncology | 2014 |
|
The oncologic role of local treatment in primary metastatic prostate cancer
P Ghadjar, A Briganti, PJ Visschere, JJ Fütterer, G Giannarini, H Isbarn, P Ost, P Sooriakumaran, CI Surcel, RC van den Bergh, IM van Oort, O Yossepowitch, G Ploussard |
World Journal of Urology | 2014 |
|
Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells
Maxwell PJ, Neisen J, Messenger J, Waugh DJ |
Oncotarget | 2014 |
|
“N of one” case reports in the era of whole genome sequencing
A. Rose Brannon, Charles Sawyers |
Journal of Clinical Investigation | 2013 |
|
Tracking clonal origin of prostate cancer
L Hutchinson |
Nature Reviews Clinical Oncology | 2013 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
|
Active surveillance and focal therapy for low-intermediate risk prostate cancer
Laurence Klotz |
Translational andrology and urology | |
|
Using somatic mutation data to test tumors for clonal relatedness
I Ostrovnaya, VE Seshan, CB Begg |
The Annals of Applied Statistics | 2015 |
|
Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study
RK Nam, Y Amemiya, T Benatar, CJ Wallis, J Stojcic-Bendavid, S Bacopulos, C Sherman, L Sugar, M Naeim, W Yang, A Zhang, LH Klotz, SA Narod, A Seth |
Journal of Cancer | 2015 |
|
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
PK Brastianos, SL Carter, S Santagata, DP Cahill, A Taylor-Weiner, RT Jones, EM van Allen, MS Lawrence, PM Horowitz, K Cibulskis, KL Ligon, J Tabernero, J Seoane, E Martinez-Saez, WT Curry, IF Dunn, SH Paek, SH Park, A McKenna, A Chevalier, M Rosenberg, FG Barker, CM Gill, PV Hummelen, AR Thorner, BE Johnson, MP Hoang, TK Choueiri, S Signoretti, C Sougnez, MS Rabin, NU Lin, EP Winer, A Stemmer-Rachamimov, M Meyerson, L Garraway, S Gabriel, ES Lander, R Beroukhim, TT Batchelor, J Baselga, DN Louis, G Getz, WC Hahn |
Cancer Discovery | 2015 |
|
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer
JJ Tosoian, M Mamawala, JI Epstein, P Landis, S Wolf, BJ Trock, HB Carter |
Journal of Clinical Oncology | 2015 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)